Each point was worked out with the data available that day. Scale 0-10: 5 is the index average and 10 is the cap (+3 standard deviations), not perfection. The vertical axis zooms to fit this company, so two charts are not comparable by eye.
Market and Valuation
Price & Market
Prev Close Price:$1,410.99
Open:$1,399.63
Day's Low:$1,393.61
Day's High:$1,437.00
Bid / Ask:-
Market Cap:1.26T
Enterprise Value:1.30T
52-Week Range
52-Week Low:$850.51
52-Week High:$1,449.68
Current position in 52-week range
52w Low-52w High
50-Day Avg:$1,200.25
200-Day Avg:$1,093.13
Volume
Volume Today:2,713,999
Avg Volume (3m):2,565,429
Avg Volume (10d):2,913,070
52-Week Change:+55.59%
vs S&P 500, 52 weeks:-
Beta:0.39
Valuation Multiples
P/E (trailing):45.74
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 29, 2026. The P/E is the price divided by that EPS.
P/E (forward):28.10
PEG Ratio:1.34
Price / Book:31.19
Price / Sales (TTM):14.52
EV / Revenue:15.05
EV / EBITDA:28.00
Dividends
Current yield:0.49%
Annual Dividend Rate:$6.92
Dividend Trailing:$6.69
Yield Trailing:0.47%
5-Year Avg Yield:0.75%
Payout Ratio:21.71%
Last Ex-Dividend Date:-
Valuation Context
P/E vs sector (indicative)
Most Recent Quarter:-
Fiscal Year (Next):-
Loading historical OHLCV database...
Date
Open
High
Low
Close
Volume
Financial Statements TTM (Trailing 12 Months)
Income Statement
Total Revenue (TTM):86.46B
Gross Profit:72.31B
EBITDA:46.49B
Net Income (TTM):27.58B
Rev Growth (YoY):+38.60%
Earnings Growth (YoY):+16.30%
Quarterly earnings growth (YoY):+15.50%
Margins
Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-
Per Share
EPS Trailing (TTM):$30.81
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 29, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$50.15
Revenue Per Share:$96.75
Cash Per Share:-
Book Value:$45.19
Last Dividend:-
Ex-Dividend Date:-
Last Split:-
Balance Sheet & Liquidity
Total cash:4.89B
Total Debt:49.50B
Net Debt (Debt - Cash):44.62B
Debt / Equity:122.93%
Current Ratio:1.39
Quick Ratio:0.64
Cash Flows
Operating Cash Flow:30.65B
Free Cash Flow (FCF):9.34B
FCF Yield (FCF / Market Cap):-
Enterprise Value:1.30T
EV / Revenue:15.05
EV / EBITDA:28.00
Profitability
ROE (Return on Equity):86.02%
ROA (Return on Assets):21.06%
P/E (trailing):45.74
P/E (forward):28.10
Price / Book:31.19
PEG Ratio:1.34
52-Week Change:+55.59%
S&P 500 change, 52 weeks:+11.37%
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
EPS Trailing (TTM):$30.81
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 29, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$50.15
P/E (forward):28.10
PEG Ratio:1.34
Growth and Margins
Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-
Per Share
Revenue Per Share:$96.75
Cash Per Share:-
Book Value:$45.19
Cash Flows (TTM)
Free Cash Flow:9.34B
Operating Cash Flow:30.65B
EBITDA:46.49B
Total Revenue (TTM):86.46B
Net Income (TTM):27.58B
Fiscal Year (Last):-
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
Quarter
Period
Actual EPS
Estimated EPS
Difference
Surprise %
Currency
Ownership Structure
Ownership Distribution
% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float
Shares & Short Interest
Shares Outstanding:890,745,031
Float (free shares):888,331,112
Short interest (shares):6,960,837
Short % of float:-
Short Ratio (days to cover):3.00
Short interest, prior month:-
Short Interest Date:-
Governance Score (1=Best, 10=Worst)
Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
Organization
Report Date
% Shares
No. Shares
Value (USD)
Change %
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
Fund
Report Date
% Shares
No. Shares
Value (USD)
Change %
Recent Insider Trades
Executive / Insider
Title
Date
Action
Shares
Options Chain
CALLS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
PUTS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
Sentiment Metrics
Put/Call Ratio (Volume):-
Put/Call Ratio (O.I.):-
Max Pain (estimated):-
Total O.I. Calls:-
Total O.I. Puts:-
Expected move
Average IV (Calls ATM):-
Average IV (Puts ATM):-
Days to Expiration:-
Expected move (±):-
Eli Lilly and Company (LLY) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Chief Scientific & Product Officer and President of Lilly Research Laboratories
52
4.90M
Ms. Anat Hakim J.D.
Executive VP, General Counsel & Secretary
56
3.34M
Mr. Jacob S. Van Naarden
Executive VP, President of Lilly Oncology & Head of Corporate Business Development
40
3.00M
Mr. Donald A. Zakrowski
Senior VP of Finance & Chief Accounting Officer
-
-
Mr. Diogo Rau
Executive VP and Chief Information & Digital Officer
50
1.06M
Mr. Michael Czapar
Senior Vice President of Investor Relations
-
-
You have seen the engine room
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.
No card. No spam.
Eli Lilly and Company (LLY): Quantitative Analysis
Eli Lilly and Company (LLY) — Healthcare — Drug Manufacturers - General. LLY is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.
So far in 2026, LLY has returned +31.6% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.
LLY ranks 33 of 461 on today's multifactor score, and 2 of the 55 Healthcare companies that score. Its strongest factor is growth (Z 1.16, ranked 32 of 489); its weakest is value (Z -0.80, ranked 475 of 489). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.
Factor scores
The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.
Eli Lilly has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 12 before the open (SEC filings through Oct 29, 2026). LLY earnings dates and times, quarter by quarter →
What is Eli Lilly's P/E ratio?
Eli Lilly's P/E (price over earnings per share for the last twelve months) is 45.7 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Sep 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Eli Lilly is above its sector median. Healthcare stocks, company by company →
Where does Eli Lilly rank on Quant500?
In the Nov 3, 2026 multi-factor ranking, Eli Lilly ranks 33 of 461, and 2 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking →How it is calculated →
Have Eli Lilly insiders bought or sold shares?
SEC Form 4 shows no open-market purchase of Eli Lilly shares from August 2025 through Nov 3, 2026. The latest sale was on Aug 17, 2026, by an officer, for $7.6M. In total, from August 2025 through Nov 3, 2026: 0 purchases and 42 sales by directors, officers and large shareholders. All LLY insider trades →
Does Eli Lilly pay a dividend?
Yes. Its dividend yield is 0.49% at the Nov 3, 2026 close (annual dividend of $6.92 per share). The next announced ex-dividend date is Nov 13, 2026.
What sector is Eli Lilly in, and which index?
Eli Lilly is classified in the Healthcare sector (industry: Drug Manufacturers - General), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →
What is behind these numbers
The concepts on this page, explained from scratch in the Academy. Free, no account.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
We save the portfolios you design, your own portfolio and your Academy progress, synced across devices.
Free, no card. Two automatic emails and no more: the one that confirms your address and the welcome one. After that, nothing you do not switch on yourself in your profile — such as the alert for insider buys, the same day they are reported to the SEC.